SOTIO to Present Biomarker Data from its SOV01 - DCVAC/OvCa Phase 2 Study in 1st line Ovarian Cancer at the 2021 ASCO Annual Meeting
SOTIO
,
a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 ASCO Annual Meeting. The presentation focuses on
potentially
combined with chemotherapy in patients with newly diagnosed epithelial ovarian carcinoma after primary debulking surgery.
SOTIO s DCVAC Program is a cell therapy platform designed to improve efficacy compared to earlier generations of dendritic cell therapies by targeting multiple antigens and applying an immune-stimulatory technique. SOTIO has created this vertically integrated, personalized cell therapy platform to enable the efficient manufacturing of product doses for one year of treatment at commercially attractive costs.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Cardiologists Can Perform Stroke Thrombectomy to Fill Unmet Need medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
April 08, 2021
It’s possible to start a successful stroke thrombectomy program in an experienced cardiac cath lab when cardiologists, neurologists, and radiologists work together closely, the experience at a single center in Prague, Czech Republic, suggests.
In the 7 years after the program launched, the team achieved outcomes similar to those seen in randomized trials conducted at experienced stroke thrombectomy centers, lead author Jakub Sulženko, MD, PhD (Charles University and University Hospital Kralovske Vinohrady), and colleagues report.
A good functional outcome defined as a modified Rankin Scale (mRS) score of 0 to 2 at 90 days was observed in 47.9% of patients, right around the 46% rate from a meta-analysis of five randomized stroke thrombectomy trials. There did not appear to be a learning curve.